Cancer immunotherapy by local transfer of autologous T lymphocytes cultured with T cell growth factor and autologous tumor extract: a clinical trial. 1983

N Kan, and K Ohgaki, and N Yamasaki, and T Hori, and N Nakayama, and Y Nio, and T Inamoto, and Y Hikasa

UI MeSH Term Description Entries
D007116 Immunization, Passive Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER). Convalescent Plasma Therapy,Immunoglobulin Therapy,Immunotherapy, Passive,Normal Serum Globulin Therapy,Passive Antibody Transfer,Passive Transfer of Immunity,Serotherapy,Passive Immunotherapy,Therapy, Immunoglobulin,Antibody Transfer, Passive,Passive Immunization,Therapy, Convalescent Plasma,Transfer, Passive Antibody
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D005260 Female Females

Related Publications

N Kan, and K Ohgaki, and N Yamasaki, and T Hori, and N Nakayama, and Y Nio, and T Inamoto, and Y Hikasa
November 1981, Cancer research,
N Kan, and K Ohgaki, and N Yamasaki, and T Hori, and N Nakayama, and Y Nio, and T Inamoto, and Y Hikasa
September 1986, Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica,
N Kan, and K Ohgaki, and N Yamasaki, and T Hori, and N Nakayama, and Y Nio, and T Inamoto, and Y Hikasa
January 1992, Cancer immunology, immunotherapy : CII,
N Kan, and K Ohgaki, and N Yamasaki, and T Hori, and N Nakayama, and Y Nio, and T Inamoto, and Y Hikasa
January 1985, Auris, nasus, larynx,
N Kan, and K Ohgaki, and N Yamasaki, and T Hori, and N Nakayama, and Y Nio, and T Inamoto, and Y Hikasa
January 1982, The Journal of experimental medicine,
N Kan, and K Ohgaki, and N Yamasaki, and T Hori, and N Nakayama, and Y Nio, and T Inamoto, and Y Hikasa
March 1983, Japanese journal of clinical oncology,
N Kan, and K Ohgaki, and N Yamasaki, and T Hori, and N Nakayama, and Y Nio, and T Inamoto, and Y Hikasa
June 1984, Nihon Geka Gakkai zasshi,
N Kan, and K Ohgaki, and N Yamasaki, and T Hori, and N Nakayama, and Y Nio, and T Inamoto, and Y Hikasa
May 1984, Gan,
N Kan, and K Ohgaki, and N Yamasaki, and T Hori, and N Nakayama, and Y Nio, and T Inamoto, and Y Hikasa
August 1983, Gan,
N Kan, and K Ohgaki, and N Yamasaki, and T Hori, and N Nakayama, and Y Nio, and T Inamoto, and Y Hikasa
January 2010, Clinical cancer research : an official journal of the American Association for Cancer Research,
Copied contents to your clipboard!